P1021: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY

MLA

Yi Zhang, et al. “P1021: Jaktinib in Patients with Myelofibrosis Who Were Intolerant to Ruxolitinib: An Open-Label, Single-Arm Phase 2B Study.” HemaSphere, vol. 7, Aug. 2023, p. e1886391. EBSCOhost, https://doi.org/10.1097/01.HS9.0000970984.18863.91.

APA

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin LI, Liangming MA, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin LI, Qingchi Liu, Wei Wang, Xu Na, Haiping Yang, Qingwei Zhao, & Jie Jin. (2023). P1021: Jaktinib in Patients with Myelofibrosis Who Were Intolerant to Ruxolitinib: An Open-Label, Single-Arm Phase 2B Study. HemaSphere, 7, e1886391. https://doi.org/10.1097/01.HS9.0000970984.18863.91

Chicago

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, et al. 2023. “P1021: Jaktinib in Patients with Myelofibrosis Who Were Intolerant to Ruxolitinib: An Open-Label, Single-Arm Phase 2B Study.” HemaSphere 7 (August): e1886391. doi:10.1097/01.HS9.0000970984.18863.91.